Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19214
Title: Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.
Austin Authors: Price, Timothy J;Thavaneswaran, Subotheni;Burge, Matthew;Segelov, Eva;Haller, Daniel G;Punt, Cornelis Ja;Arnold, Dirk;Karapetis, Christos S;Tebbutt, Niall C ;Pavlakis, Nick;Gibbs, Peter;Shapiro, Jeremy D
Affiliation: Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Cabrini Medical Centre, Monash University, Melbourne, Australia
Medical Oncology, Royal North Shore Hospital, Sydney University, Sydney, Australia
Medical Oncology, Royal Melbourne and Western Hospitals, Melbourne, Australia
Abramson Cancer Centre, University of Pennsylvania, Philadelphia, USA
Medical Oncology, The Queen Elizabeth Hospital, Adelaide Colorectal Tumour Group and University of Adelaide, Adelaide, Australia
Medical Oncology, Klinik für Tumorbiologie, Freiburg, Germany
Medical Oncology, Flinders Medical Centre, Flinders University and Adelaide Colorectal Tumour Group, Adelaide, Australia
St Vincent's Clinical School, Faculty of Medicine, University of NSW, Sydney, Australia
Medical Oncology, Royal Brisbane Hospital, Brisbane, Australia
Medical Oncology, University of Sydney and CTC, Sydney, Australia
Issue Date: May-2016
Publication information: Expert review of anticancer therapy 2016; 16(5): 557-71
Abstract: The treatment of metastatic CRC (mCRC) has evolved over the last 20 years, from fluoropyrimidines alone to combination chemotherapy and new biologic agents. Median overall survival is now over 24 months for RAS mutated (MT) patients and over 30 months for RAS wild-type (WT) patients. However, there are subgroups of patients with BRAF V600E MT CRC who have a significantly poorer outlook. Newer treatment options are also being explored in select subgroups of patients (anti-HER 2 in HER2 positive mCRC and immunotherapy in patients with defective mismatch repair (dMMR)). The best use of these systemic treatment options, as well as surgery in well-selected patients requires careful consideration of predictive biomarkers and importantly, the optimal sequence in which therapies should be given to derive maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, USA, The Netherlands and Germany met during ECCO 2015 in Vienna to review current practice.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19214
DOI: 10.1586/14737140.2016.1170594
PubMed URL: 27010906
Type: Journal Article
Subjects: Colorectal cancer
Consensus
RAS
VEGF
biological
chemotherapy
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.